Next-gen AAV gene therapy delivery market seen nearly doubling by 2030

The next-generation adeno-associated virus gene therapy delivery market is projected to grow from $4.96 billion in 2025 to $11.91 billion by 2030, driven by targeted therapies, vector engineering and more clinical trials. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Next-generation AAV delivery is central to making gene therapies more precise, durable and safer. - The market is expanding fast as rare disease research, precision medicine and commercialization accelerate. - The size of the market signals where biotech investment and manufacturing capacity may concentrate over the next several years.

What happened: - The Business Research Company released a 2026 report on the global next-generation adeno-associated virus gene therapy delivery market. - The market is estimated at $4.96 billion in 2025 and is projected to reach $5.93 billion in 2026. - The report forecasts the market will grow to $11.91 billion by 2030, implying a 19.1% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth through the forecast period.

The details: - Next-generation AAV delivery uses engineered AAV capsids to improve therapeutic gene delivery to target cells. - The technology aims to improve tissue-specific targeting, reduce immune reactions and support longer-lasting gene expression. - Growth drivers include stronger gene therapy research, more rare genetic disorder cases, higher biotech investment and a rising number of AAV-related clinical trials. - The report also points to growing demand for more targeted therapeutic solutions. - The market report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report highlights engineered AAV capsid technologies, methods to reduce immune responses, long-lasting gene expression systems, broader rare-disease applications and scalable manufacturing as emerging trends.

Between the lines: - The market outlook suggests gene therapy delivery is shifting from experimental capability to a more commercial platform race. - Faster clinical trial activity indicates broader confidence in targeted gene therapies and more demand for delivery systems that can improve outcomes. - Manufacturing scalability stands out as a practical bottleneck and opportunity as adoption expands. - In January 2024, the American Society of Gene & Cell Therapy reported a 10% increase in gene therapies entering Phase III trials in Q4 2023 versus the prior quarter, the first increase since mid-2022.

What's next: - The market is expected to keep expanding as personalized gene therapies gain wider use. - Advances in AAV vector engineering and precision medicine should continue to shape product development. - Commercialization of gene therapy products is likely to lift demand for delivery platforms that can be manufactured at scale. - The company is offering updated report features including TAM analysis, company scoring matrices, dashboards, infographics and refreshed graphics and tables.

The bottom line: - Next-generation AAV delivery is becoming a core enabling market for gene therapy, with rapid growth now projected through 2030.